The B.1.1.7 variant of SARS-CoV-2, which was first identified in the UK, may be associated with an increased risk of death, a Nature study suggests.
Roche to acquire GenMark Diagnostics, Inc., to access platform to test for broad range of pathogens with one patient sample.
While media reports suggest AstraZeneca’s COVID-19 jab might have caused blot clots, the EMA didn’t confirm a causal relationship.
Swiss Roche AG has missed the primary endpoint in the REMDACTA trial in patients with severe COVID-19 pneumonia.
Danish sustainable crop protection company, BioPhero AS, has raised $17m in Series A funding led by DCVC Bio.
German researchers have presented a new method to assess on-target and off-target effects of CRISPR-Cas nucleases or TALENs.
EMA’s human medicines committee has started a rolling review of Sputnik V, a COVID-19 vaccine developed by Russia’s Gamaleya National Centre of Epidemiology and Microbiology.
Chemieanlagenbau Chemnitz (CAC) is realizing one of the first large-scale plants in Europe to use innovative co-processing to produce carbon-neutral fuels.
Kurma Parnters and Francee investment bank have launched a €50m project named Argobio that is aimed at identifiying the most genious biotech ideas and spin out companies.
British Oxular Ltd has raised $37m in a financing round led by Forbion Parners and co-financed by IP Group, NeoMed, and V-Bio Ventures to push its pipeline.